- Deutsche Bank downgraded Ozempic maker Novo Nordisk to sell after the stock fell 70% from its peak.
- The downgrade marks a break from Wall Street analysts' prior reluctance to advise investors to sell Novo Nordisk shares.
Quotes
“Wall Street analysts have still been reluctant to advise investors to sell the stock”